Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria

An antibacterial composition and an inflammation-inducing technology, which can be used in antibacterial drugs, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve problems such as intestinal colonization of unconfirmed bacterial strains, and achieve the effect of improving or preventing diseases

Pending Publication Date: 2021-10-29
KEIO UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Furthermore, the present inventors found that when Kp2H7 strains were orally administered to SPF (specific-pathogen-free) mice, unlike the above-mentioned germ-free mice, intestinal colonization of these bacterial strains was not confirmed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria
  • Antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria
  • Antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0184] Such as figure 1 As shown in the upper part of , Klebsiella 2H7 strain (Kp2H7) was administered to germ-free mice, and a stool sample of a healthy volunteer was administered one week later.

[0185] Specifically, for germ-free mice, C57BL / 6N (Japan CLEA Co., Ltd.) 4 to 8-week-old mice were kept in plastic isolators (aseptic isolators) (manufactured by ICM Co., Ltd.; ICM-1B). , fed with free drinking water for more than 1 week, and used after acclimatization to the environment. The age at the beginning of the experiment ranged from 8 to 14 weeks. The same applies to other examples in this specification.

[0186] Put the bacterial liquid of Klebsiella into LB liquid medium and culture it overnight at 37°C, adjust the OD value to 1.2 (equivalent to 1*10^9CFU / mL), and use a probe to inject 200μL / ( Bacterial solution equivalent to 2*10^8CFU / monkey) was administered to the stomach of mice.

[0187] Regarding stool samples, stools provided by healthy Japanese volunteers (#...

Embodiment 2

[0191] (Embodiment 2) Bacteria is isolated from healthy volunteer's feces

[0192] The frozen stool samples derived from the stools (F stools, K stools, and I stools) from healthy people F, K, and I prepared in Example 1 were thawed at room temperature, diluted with PBS, and placed in EG medium. , modified GAM agar medium (Nissui Pharmaceutical Co., Ltd.; 05426), REINFORCED CLOSTRIDIAL AGAR (RCM AGAR) (Thermo Fisher Scientific Inc; CM0151) or Schaedler blood medium (manufactured by Wako; 517-45805) In 37℃, 10% CO 2 The culture was carried out under anaerobic environment, and the colonies formed were isolated. 37 strains were isolated from F stool, 42 strains were isolated from I stool, and 47 strains were isolated from K stool. Afterwards, K was isolated again, and finally 68 strains were isolated from K.

[0193] The isolated bacteria were analyzed by 16SrDNA using the Sanger method to analyze the gene sequence and estimate the bacteria. Sequencing analysis was performed ...

Embodiment 3

[0200] Such as image 3 As shown in the upper part, Kp2H7 was administered to germ-free mice, and the mixed isolates (37 strains (F37mix) derived from F stool, 42 strains (I42mix) derived from I stool, and 42 strains (I42mix) derived from K Just 47 strains (K47mix)) or 1 just.

[0201] The isolated bacteria use mGAM liquid medium, EG medium or CM0149 medium, cultured in an anaerobic chamber at 37°C for 24-48 hours and mixed. The mixture was concentrated 5 times, and 200 μL / monkey (total bacteria amount equivalent to 1*10^9 CFU / bird) of the bacterial solution was administered into the stomach using a probe. The administration of the mixed isolated strains in the following examples was also carried out in the same manner.

[0202] The result is as image 3 As shown in the lower part (graph), it is shown that the 37 strains derived from F feces are related to the elimination ability of Klebsiella from the intestinal tract of mice, and have the same activity as I feces.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria containing intestinal bacteria as an active ingredient or a pharmaceutical composition for treating, improving, or preventing infectious disease and inflammatory disease, etc.

Description

technical field [0001] The invention relates to an antibacterial composition for drug-resistant bacteria or inflammation-inducing bacteria. In addition, the present invention relates to a pharmaceutical composition or method for treating, improving or preventing diseases caused by drug-resistant bacteria or inflammation-inducing bacteria. Background technique [0002] A variety of normal bacteria often exist in the mucous membranes of the digestive tract or oral cavity, and they form a flora as a whole. The normal flora plays an important role in the physiology or health maintenance of the host. Abnormal composition of normal flora is called Dysbiosis, and it has been gradually elucidated as the cause of various diseases. Further insight into the normal flora of the mucosa is highly likely to contribute to the development of new disease countermeasures or treatments for various diseases, but due to its complexity, its detailed mechanisms are still not fully elucidated. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P31/04A61K35/741
CPCA61P31/04A61K35/741
Inventor 本田贤也安间惠子新幸二成岛圣子古市宗弘河口贵昭
Owner KEIO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com